Typicality: | 0.438 |
Saliency: | 0.442 |
to assess tolerability | 22 | purpose |
once weekly | 2 | temporal |
trial → be designed to evaluate → pharmacokinetic | 16 |
trial → be designed to assess → pharmacokinetic | 15 |
trial → be designed to assess → pharmacodynamic | 13 |
trial → be designed to evaluate → pharmacodynamic | 3 |
negative | neutral | positive |
0.022 | 0.878 | 0.099 |
Raw frequency | 47 |
Normalized frequency | 0.442 |
Modifier score | 0.500 |
Perplexity | 66.303 |